Member Info for Mafuta

It sure does NOT matter if they are in or out (or doing the hokey cokey for that matter) what does matter is that SAR has the money in the bank and can use it for development of their pipeline ... it might even be good not to know who the individuals are in any case ... LH&K Mafuta

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the publication of an international patent in relation to the Company's NXP004 asset, which comprises novel forms of olaparib (the "Patent"). Olaparib is currently marketed by AstraZeneca, under the Lynparza® brand name for the treatment of adults with suspected deleterious germline or somatic BRCA gene mutated ovarian, breast, or pancreatic cancer, or for suspected deleterious germline or somatic HRR gene mutated prostate cancer.

BTW your reference to Jesus speaks of religious intolerance and has been reported

James you need to wind your neck in mate ... I tried to join but was prevented due to a number of obstacles I could not overcome ... All you have done lately is to support the MMs and contradict anyone who has a contradictory view to yours ... Sorry but not being in your exclusive club is no loss's to me either ... But for what it's worth LH&K Mafuta

Danny it's been a rather poorly kept secret that the brokers do not want the PIs so heavily invested here and they have been trying every trick in the book to break our resolve ... They have had limited success and their time is getting short ... Soon they will try some other tricks and no doubt will meet with the same resolve ... Keep calm and don't panic ... Great to have you back Danny

Yes ... AZ may well be on a bit of a shopping spree at the moment ;0)

Just remember you can always use the filter button

That's sad news indeed ... Despite the relaxed attitude of many Covid is still menacing society and robbing families of loved ones ... My sincere condolences to the family ... Mafuta

GlaxoSmithKline PLC said on Friday that the US Food & Drug Administration has amended the emergency use authorization fact sheet for sotrovimab, an investigational Covid-19 neutralizing monoclonal antibody.

The Brentford, England-based pharmaceutical company explained that the FDA determined that it is unlikely that the sotrovimab 500 milligram dose will be effective against the Omicron BA.2 variant.

GSK and Vir Biotechnology Inc are now preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 sub-variant and will be sharing these data with regulatory and health authorities around the world for discussion.

Sotrovimab is authorized for emergency use in the United States and has been granted a marketing authorization in the European Union as well as conditional marketing authorization in the UK.

It never ceases to amaze me why people need to say they are a LTH or a VLTH ... it matters not a jot ... what does matter is that you ARE invested .... each will have their own investment strategies, day trade, short, medium, long term etc. and TBH that's their own business ... when you make a decision to invest you will likely have your exit points in mind ... lower and upper ... so although one may get quite emotional when the share fails to perform and when it does perform, at the end of the day it's an investment decision. LH&K Mafuta

Every little helps

Nick sorry to hear your predicament ... best wishes for you and the missus as you weather this storm together ... kind regards Mafuta

Good news ... and why don't they wait to release it? ... The clue is in the R of RNS ... regulatory news has to be released in a reasonable time frame and cannot be delayed for manipulative purposes ... if it was a reach announcement that would be different ... it's the NOMAD who calls the shots not the BOD ... glad to see the market responding though ... LH&K Mafuta

the clue is in the silence ... as the song goes ... silence is golden

UP 11% (Google Finance) not as much as we would have wanted bit guess it's in the right direction and 1.9 Pounds is not a bad prediction for the time being .... (Ducking missiles)

Time for bed ... Said Zebedee ... ;0)

I echo the sentiments of all who have sent you messages of encouragement notalot. With a world full of bad news and sorrows it's good to hear some good news for a change. Warm regards to you and yours. Mafuta

Its a bit previous to blame Peel Hunt ... yet ... as we don't really know what they are doing behind the scenes ... but Medistrava are the ones that need to pull their fingers out and earn their fees ...

When I say taken to account I mean the PR company not the BOD

Warty I totally agree PR is very poor and one wonders what they are being paid for. They should be taken to account. Love hugs and kisses Mafuta